Wyatt, AW; Litiere, S; Bidard, FC; Cabel, L; Dyrskjøt, L; Karlovich, CA; Pantel, K; ... The RECIST ctDNA workshop group; + view all Wyatt, AW; Litiere, S; Bidard, FC; Cabel, L; Dyrskjøt, L; Karlovich, CA; Pantel, K; Petrie, J; Philip, R; Andrews, HS; Vellanki, PJ; Tolmeijer, SH; Alberu, XV; Alfano, C; Bogaerts, J; Calvo, E; Chen, AP; Toledo, RA; De Vries, EGE; Seymour, L; Laurie, SA; Garralda, E; Alix-Panabières, C; Attard, G; Dancey, J; Ford, R; Ignatiadis, M; Mateo, J; Mizoguchi, C; Mizusawa, J; Needham, J; Parsons, H; Rolfo, C; Rothwell, D; Schwartz, L; Shankar, L; Shaw, J; Stewart, M; Sudo, K; Williams, M; Tie, J; Yap, C; The RECIST ctDNA workshop group; - view fewer (2024) Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group. Clinical Cancer Research , 30 (22) pp. 5034-5041. 10.1158/1078-0432.CCR-24-1883.

Text Final version 02Sept2024 - CCR-24-1883R1_Merged_PDF.pdf - Accepted Version Access restricted to UCL open access staff until 16 November 2025. Download (281kB)

Abstract

Early indicators of metastatic cancer response to therapy are important for evaluating new drugs and stopping ineffective treatment. The RECIST guidelines based on repeat cancer imaging are widely adopted in clinical trials, are used to identify active regimens that may change practice, and contribute to regulatory approvals. However, these criteria do not provide insight before 6 to 12 weeks of treatment and typically require that patients have measurable disease. Recent data suggest that measuring on-treatment changes in the amount or proportion of ctDNA in peripheral blood plasma may accurately identify responding and nonresponding cancers at earlier time points. Over the past year, the RECIST working group has evaluated current evidence for plasma ctDNA kinetics as a treatment response biomarker in metastatic cancers and early endpoint in clinical trials to identify areas of focus for future research and validation. Here, we outline the requirement for large standardized trial datasets, greater scrutiny of optimal ctDNA collection time points and assay thresholds, and consideration of regulatory body guidelines and patient opinions. In particular, clinically meaningful changes in plasma ctDNA abundance are likely to differ by cancer type and therapy class and must be assessed before ctDNA can be considered a potential pan-cancer response evaluation biomarker. Despite the need for additional data, minimally invasive on-treatment ctDNA measurements hold promise to build upon existing response assessments such as RECIST and offer opportunities for developing novel early endpoints for modern clinical trials.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item